Jesse Salk, MD, PhD speaking engagement October 25th 2018
Detection of Rare and Subclonal Mutations by Next-Generation Sequencing For Cancer Risk Assessment
Genomics Working Group Meeting
Health Canada, Ottawa, ONT
Jesse Salk, MD, PhD speaking engagement October 24th 2018
Direct Quantification of in vivo Chemical Mutagenesis Using Duplex Sequencing
Environmental Health Science and Research Bureau’s Seminar Series
Health Canada, Ottawa, ONT
Jesse Salk, MD, PhD speaking engagement September 26th 2018
Detection of Rare and Subclonal Mutations by Next-Generation Sequencing
Annual Meeting of the Environmental Mutagenesis and Genomics Society
Hyatt Regency, San Antonio, TX
NOTE: Dr Salk’s talk will be followed directly by
Application of Duplex Sequencing™ for In Vivo Mutation Detection Robert R. Young, BioReliance Corporation

TwinStrand to Attend Genome Rearrangements and Mutation Signatures in Development and Cancer
April 18-29, 2017, Boston, MA

TwinStrand to Talk at the American Association for Cancer Research
Duplex Sequencing™ detects cancer-associated mutations arising during normal aging: Clonal evolution over a century of human lifetime
4 PM EST, April 3, 2017, Washington, D.C.

Startup TwinStrand Biosciences Aims to Commercialize Duplex Sequencing™ Technology
March 9, 2017, by Monica Heger, GenomeWeb

NEW YORK (GenomeWeb) – University of Washington spinout TwinStrand Biosciences has raised around $2 million in seed funding and opened a next-generation sequencing laboratory in Seattle. The startup plans to commercialize technology known as Duplex Sequencing™ for applications such as oncology and forensics…

… “When your sensitivity improves enough to get above the technical background, we see mutations that occur in healthy people that look identical to mutations that occur in cancer,” Salk said. And, he added the mutations occur at different levels depending on the person’s age and environmental exposures. “Just seeing a mutation that looks like a cancer mutation doesn’t mean that you have cancer,” he said. And, the work highlights the challenges of using liquid biopsy analysis to screen healthy individuals for cancer.

TwinStrand Awarded Poster Competition Winner at Molecular Medicine TRI-CON 2017
February 22, 2017, San Francisco, CA

TwinStrand to Attend Advances in Genome Biology and Technology Annual Meeting
February 13-16, 2017, Hollywood Beach, FL